ClinicalTrials.gg
RecruitingNCT05979948CZ-WM01Updated Sep 14, 2023

A Phase 2 Clinical Trial to Evaluate Zanubrutinib Combined With BR (Bendamustine/Rituximab) Regimen in Subjects With Newly-diagnosed Waldenström's Macroglobulinemia

A Phase 2 interventional study of Zanubrutinib and Bendamustine in Waldenström's Macroglobulinemia, sponsored by Shanghai Changzheng Hospital. Recruiting at 1 site in China. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2023-09-14.

Sponsored by Shanghai Changzheng Hospital · Phase 2, Interventional, and Treatment

How we know

From the registry’s dates

  • Primary completion was expected by Apr 2025, 1 year 7 months ago, but the record still lists the study as recruiting.
  • Started Aug 2023; still recruiting 3 years 3 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
60
Allocation
Not applicable
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 10 studies testing bendamustine in Waldenstrom Macroglobulinemia — 4 open to participants now, 7 under way, none of them phase 3. bendamustine · Waldenstrom Macroglobulinemia.

Planned enrollment
4th of 10
60 · median 48
Started
2023
with 1 other
Phase 2
5 of 10
2 open now
Registered
7th of 10
by date
Lead sponsor
1 of 10
Shanghai Changzheng Hospital

Among the 10 studies testing bendamustine in Waldenstrom Macroglobulinemia, this one is the 4th largest by planned enrollment, is one of 2 that started in 2023, is one of 5 in phase 2, and was the 7th registered.

Waldenstrom Macroglobulinemia

524 studies on the registry are indexed under Waldenstrom Macroglobulinemia; 61 are open to participants now.

Browse Waldenstrom Macroglobulinemia studies →

Open to participants now

4 of the 10 studies testing bendamustine in Waldenstrom Macroglobulinemia are open now, in 2 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 4 open studies →

Where they have run

About bendamustine

bendamustine: first FDA approval 2008 (TREANDA). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 47 Waldenstrom Macroglobulinemia studies recruiting now, 43 (91%) set no upper age limit and 1 (2%) stops at 75 or younger; 2 take children under 18; none take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 10 studies testing bendamustine in Waldenstrom Macroglobulinemia, or all of them as a file.
02

Study summary

This was a single-arm, multicenter, Phase 2 study to evaluate the efficacy of zanubrutinib combined with BR (Bendamustine/Rituximab) regimen in Chinese participants with newly-diagnosed Waldenström's macroglobulinemia who exhibited one or more of the criteria for requiring treatment based on consensus guidelines from the 11th International Workshop on Waldenström's Macroglobulinemia (IWWM). The investigators propose this combination will improve the deep remission compared to single Zanubrutinib or BR regimen and can be a time-limited regimen which will reduce the life-time therapy and benefit the patients.

Read the detailed description

The study comprised an initial screening phase (up to 7 days), a single-arm treatment phase, and a follow-up phase. Subjects with newly-diagnosed Waldenström's macroglobulinemia can participate if all eligibility criteria are met. The participants will receive bendamustine and rituximab for 6 28-day cycles. Bendamustine will be given intravenously at 70-90 mg/m2 on days 1 and 2 of each cycle. Rituximab will be given on day 1 of each cycle (375 mg/m2 intravenously), Zanubrutinib will be given orally 160mg Bid per day, up to 12 months. The participants with WM will also have disease assessment with Lymph node ultrasound and abdominal ultrasound each cource, serum IgM, serum protein electrophoresis (SPE), immunofixation (IFA), and viscosity assessments will be measured serially. A bone marrow aspiration and biopsy flow cytometry examination will be done before treatment and at response assessment at cycle 6 and 12. Durability of response will also be assessed every 3 months after treatment.

03

Conditions studied

  • Waldenström's Macroglobulinemia

Keywords

  • Waldenström's macroglobulinemia
  • Zanubrutinib
  • BR regimen
  • newly-diagnosed
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Subjects must meet all of the following criteria to be enrolled:

  1. Newly diagnosed patients with waldenström's macroglobulinemia meeting at least one criterion for treatment according to consensus panel criteria from the eleventh IWWM.
  2. score: 0-3 points, estimated survival time exceeding 3 months.
  3. Did not receive any treatment for Waldenström's macroglobulinemia before screening, except for therapy for hemolysis.
  4. No serious damage to main organs, and meet the following laboratory examination indicators: rate≥40ml/min, total ≤1.5 times of the ; and ALT≤2.5 times of the upper limit of normal range; Myocardial enzyme≤2 times of the upper limit of normal range; ECHO must demonstrate (LVEF) within the normal range, and no abnormality with clinical significance.
  5. ≥1.5×10\^9/L without growth factor therapy within 7 days before screening; count≥50×10\^9/L without growth factor support or transfusion within 7 days before screening; ≥60 g/L without erythropoietin (EPO) support or transfusion within within 7 days before screening.
  6. No history of paroxysmal atrial fibrillation or chronic persistent atrial fibrillation.
  7. Able to swallow and Oral administration.
  8. The subjects complete all screening and evaluations listed in all trial protocols.
  9. The subjects who signed the form for chemotherapy.

Exclusion criteria

Exclusion Criteria:

  1. Waldenström's macroglobulinemia with amyloidosis or POEM syndrome
  2. positive, or patients with active hepatitis A, , and infection; Or the number of copies of hepatitis B virus>10\^2.
  3. Accompanied by other serious unstable diseases, including heart failure, renal failure, liver failure, hemorrhagic diseases, uncontrollable diabetes, etc.
  4. In the past two years, the terminal organ was damaged due to diseases (such as Crohn's disease, rheumatoid arthritis, systemic lupus erythematosus), or the systemic use of or other systemic disease control drugs was required.
  5. Serious infectious diseases (uncured pulmonary tuberculosis, pulmonary aspergillosis, etc.).
  6. Other uncontrolled (excluding non Melanoma skin cancer, cervical cancer in situ, bladder cancer cancer and breast cancer with disease-free survival of more than 5 years).
  7. Individuals with epilepsy, dementia, and other mental disorders who require medication treatment and are unable to understand or follow the research protocol.
  8. Drug use, medical, psychological, or social conditions that may interfere with participants' participation in the study or evaluation of the results.
  9. Pregnant and lactating women.
  10. Patients who are accounted to be not appropriate for this trail by investigator.
Terms in these criteria, in plain language(18)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
60 participants (estimated)

Study arms

  • Experimental
    zanubrutinib combined with BR regimen

    Drug: zanubrutinib,160 mg oral capsules twice daily for 12 months Drug: Bendamustine,70-90 mg/m2 on days 1 and 2 of each cycle for 6 cycles. Drug: Rituximab,375 mg/m2 intravenously on day 0 of each cycle for 6 cycles.

    Drug: Zanubrutinib · Drug: Bendamustine · Drug: Rituximab

Interventions

  • Zanubrutinib, 160 mg oral capsules twice daily for 12 months

  • Bendamustine, 70-90 mg/m2 on days 1 and 2 of each cycle for 6 cycles.

  • Rituximab, 375 mg/m2 intravenously on day 0 of each cycle for 6 cycles

06

What researchers measure

Primary outcomes

  1. Overall Response Rate (ORR)

    ORR is defined as the percentage of participants with a minor, partial, very good partial, and complete response

    Time frame: up to the end of 12 cycles of treatment(each cycle is 28 days)

  2. The best deep response rate

    defined as complete response (CR) and very good partial response (VGPR)

    Time frame: Time Frame: up to the end of 12 cycles of treatment(each cycle is 28 days)

Secondary outcomes

  1. Progression-free Survival (PFS)

    PFS was defined as from the initiation of treatmentuntil to first documentation of progression or death, whichever comes first.

    Time frame: Up to 6 years post first dose

  2. Overall Survival (OS)

    OS is measured from the date of the initial of treatment to the date of the subject's death.

    Time frame: Up to 6 years post first dose

  3. minimal residual disease (MRD) rate

    MRD will be assessed at two on treatment timepoints (before start of cycles 7, 12) and every 6 months thereafter. MRD will be measured through bone marrow samples using flow cytometrey.

    Time frame: Up to 6 years post first dose

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Aug 2023 (actual). Primary completion is estimated for Apr 2025, 20 months after the start.

Of 55 non-industry phase 2 interventional studies under Waldenstrom Macroglobulinemia, half reached primary completion within 67 months of starting (the median), counting those still running; a quarter within 45 and three quarters within 109. This study's planned 20 months is below that.

Counting every sponsor, half of 66 studies reached it within 64 months; a quarter within 45 and three quarters within 103.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 30, 2023
First posted
Aug 7, 2023
StartActual
Aug 1, 2023
Primary completionEst.
Apr 1, 2025
CompletionEst.
Dec 1, 2025
Last update
Sep 14, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 14, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05979948
Collaborators
RenJi Hospital, Huashan Hospital, Shanghai 6th People's Hospital, Huadong Hospital
Responsible party
Juan Du (Director, Shanghai Changzheng Hospital) — Principal investigator
First posted
Aug 7, 2023
Start date
Aug 1, 2023
Primary completion
Apr 1, 2025 (estimated)
Completion
Dec 1, 2025 (estimated)
Last update
Sep 14, 2023

Study contacts

Haiyan He, Master
Contact
doctorhehaiyan@126.com
+8613661513012
Juan Du, Doctor
principal investigator · Shanghai Changzheng Hospital

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Zanubrutinib · Bendamustine · Rituximab

Start the discussion